Partner's Meeting

Journal of Cancer Metastasis and Treatment (JCMT) is an international peer-reviewed, open access, online journal.

Aims and Scope

The journal concerns cancer metastasis and treatment, including the occurrence, development, progression, metastasis, and treatment of neoplastic diseases. Its coverage includes basic, translational and clinical studies related to cancer cell biology, genomics, precision medicine, medical oncology, radiation and immunotherapy and different types of solid and liquid cancers. Articles in the following areas are especially welcome:

  • Basic research on cancer occurrence and progression, focusing on molecular biology, cell biology, and genetics;
  • Mechanisms of metastasis and its prevention and control;
  • Basic and clinical research on treatment of primary, metastatic tumors;
  • Improved methods for medical, radiological, and/or surgical treatment of metastatic tumors (immunotherapy, chemotherapy, radiotherapy, biological therapy, operative treatment, interventional therapy, etc.);
  • Observational/epidemiological studies focusing on environmental and behavioral factors that reduce the risk of cancer progression and metastasis and gene/environment interactions;
  • Primary and secondary prevention studies.

To enhance the interdisciplinary scope of the journal and expand its coverage to include broader research areas, the journal proposes incorporating the following interdisciplinary researches:

  • Bioinformatics and Computational Biology: Integrating computational methods to analyze large-scale datasets, such as genomic sequencing data, to identify biomarkers, therapeutic targets, and pathways involved in cancer metastasis and treatment response.
  • Systems Biology Approaches: Utilizing systems biology approaches to understand the complex interactions between cancer cells, immune cells, stromal cells, and the tumor microenvironment in driving metastasis and therapeutic resistance.
  • Nanotechnology and Drug Delivery: Exploring nanotechnology-based approaches for targeted drug delivery, imaging, and therapy monitoring in cancer treatment, with a focus on overcoming barriers to effective treatment of metastatic tumors.
  • Immunotherapy and Immunology: Investigating the role of the immune system in cancer progression and metastasis, and exploring novel immunotherapeutic strategies, such as immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines.
  • Precision Oncology and Personalized Medicine: Advancing precision oncology approaches by integrating histopathological as well as molecular diagnostics, genomics, proteomics, and other omics technologies to tailor treatment strategies based on the individual genetic profile of patients and tumor heterogeneity.
  • Biomedical Engineering and Medical Devices: Developing innovative medical devices and technologies for early detection, diagnosis, and treatment monitoring of metastatic cancer, including imaging modalities, biosensors, and minimally invasive surgical techniques.
  • Psycho-Oncology and Behavioral Sciences: Investigating the psychosocial and behavioral factors influencing cancer progression, treatment adherence, and quality of life in patients with metastatic cancer, and developing interventions to support their emotional and psychological well-being.
  • Environmental and Occupational Health: Examining the impact of environmental pollutants, occupational exposures, lifestyle factors, and socioeconomic determinants on cancer risk, progression, and metastasis, and identifying preventive measures to mitigate these risks.
  • Regenerative Medicine and Tissue Engineering: Exploring regenerative medicine approaches to repair and regenerate tissues damaged by metastatic tumors or cancer treatments, including tissue-engineered constructs, stem cell therapy, and organoid models for drug screening.
  • In vitro 3D cellular models (tumoroids, organoids, bioprinting) for studying the cancer growth, the tumor microenvironment, the invasiveness, and for drug screening as replacement of animal models.
  • Bioethics and Health Policy: Addressing ethical considerations and policy implications of emerging technologies and interventions in cancer research and treatment, including issues related to access to care, patient autonomy, and informed consent.

JCMT publishes high-quality the Original Article, Review/Systematic Review, Meta-Analysis, Technical Note, Commentary, Editorial, Opinion, Perspective, Letter to Editor, etc.


The journal is owned by OAE Publishing Inc.

Publishing Model

Gold open access. All articles published by JCMT are made freely and permanently accessible online immediately from the date of publication. For further information, please refer to Open Access.

Copyright and License to Publish

Articles in JCMT had been published under Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0) by October 2017, whereas the Creative Commons Attribution 4.0 International (CC BY 4.0) was further adopted afterwards. The CC BY 4.0 allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.

Copyright is retained by authors. Authors are required to sign a License to Publish (which can be downloaded from the journal's Author Instructions), granting JCMT, which identifies itself as the original publisher, exclusive rights to publish their articles, and granting any third party the right to use the articles freely as long as the integrity is maintained and the original authors, citation details and publisher are identified.

Editorial Board

For more information about the editorial team, please refer to Editorial Board.

Peer Review

The journal adheres to a rigorous peer review process and undergoes single-blind peer review. For more details, please refer to Editorial and Peer Review Process and Peer Review Guidelines.

Publication Ethics Statement

Journal of Cancer Metastasis and Treatment is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best Practice Guidelines.

The Editors of this journal enforce a rigorous peer-review process together with strict ethical policies and standards to guarantee to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, image manipulation, inappropriate authorship credit, and the like, do arise. The Editors of Journal of Cancer Metastasis and Treatment take such publishing ethics issues very seriously and are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use CrossCheck (powered by iThenticate) to check submissions against previous publications.

Editorial Policies

All manuscripts submitted to JCMT should adhere to JCMT's Editorial Policies.

Journal Information and Statistics

  • Launch date: April 15, 2015
  • Publication model: Open access
  • ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
  • Digital archive: Portico
  • Frequency: Continuously published
  • DOI: 10.20517/2394-4722

Indexing & Archiving


Please see our Contact Us page for details about different queries.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: